Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

Leukemia

Volumn 17, Issue 3, 2003, Pages 604-611

  Zhu, Z ^a   Hattori, K ^b   Zhang, H ^a   Jimenez, X ^a   Ludwig, D L ^a   Dias, S ^b   Kussie, P ^a   Koo, H ^a   Kim, H J ^a   Lu, D ^a   Liu, M ^a   Tejada, R ^b   Friedrich, M ^b   Bohlen, P ^a   Witte, L ^a   Rafii, S ^b  

^a ELI LILLY AND COMPANY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Antibody affinity; Antibody engineering; Autocrine tumor growth; Human antibody; Leukemia; VEGF KDR

Indexed keywords

CETUXIMAB; IMC 1121; IMC 1C11; IMC 2C6; IMMUNOGLOBULIN F(AB) FRAGMENT; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LEUKEMIA; LEUKEMIA CELL; METASTASIS; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; SURVIVAL TIME; TUMOR GROWTH;

EID: 0344839087     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402831     Document Type: Article

References (55)

1. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-543.
2. Klagsbrum M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-276.
3. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
4. Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 2002; 4: 20-28.
5. Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002; 2: 135-156.
6. Zogakis TG, Libutti SK. General aspects of anti-angiogenesis and cancer therapy. Exp Opin Biol Ther 2001; 1: 253-275.
7. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
8. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
9. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
10. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398-1401.
11. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
12. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
13. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
14. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
15. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 19991; 94: 3717-3721.
16. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 768-770.
17. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001; 7: 795-799.
18. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemia cell growth and migration. J Clin Invest 2000; 106: 511-521.
19. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-1913.
20. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
21. Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 2000; 60: 2527-2534.
22. Fiedler W, Staib P, Kuse R, Duhrsen U, Flasshove M, Cavalli F et al. Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J Supl 2001; 3: S129-S133.
23. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001; 28: 551-559.
24. List A. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. The Oncologist 2001; 6: 24-31.
25. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
26. Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241-243.
27. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001; 97: 1413-1421.
28. Zhu Z, Hicklin DJ, Bohlen B, Waskal H, Witte L. Clinical development of antibody-based receptor tyrosine kinase inhibitors for cancer therapy. In: Recent Research Developments in Cancer, Vol. 3. Trivandrum: Transworld Research Network, 2001; pp 369-384.
29. Glennie MJ, Johnson PWM. Clinical trials of antibody therapy. Immunol Today 2000; 21: 403-410.
30. Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998; 58: 3209-3214.
31. Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T et al. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett 1999; 136: 203-213.
32. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97: 393-399.
33. Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L et al. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J Biol Chem 2000; 275: 14321-14330.
34. De Haard HJ, va Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx de P et al. A large non-immunized human Fab fragment phage library that permit rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274: 18218-18230.
35. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B et al. Placenta growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone marrow microenvironment. Nat Med 2002; 8: 841-849.
36. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-flt1. Nat Med 2002; 8: 831-840.
37. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61: 1207-1213.
38. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17: 155-161.
39. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K et al. Antivascular endothelial growth factor receptor (Fetal Liver Kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-5218.
40. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
41. Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77: 933-936.
42. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell JT et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
43. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
44. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000; 6: 2094-2103.
45. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates hemotopoietic stem cell survial by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
46. Ziegler BL, Valtieri M, Porada GA, De Maria R, Muller R, Masella B et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 1999; 285: 1553-1558.
47. Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Writte L et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 2001; 61: 7002-7008.
48. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000; 19: 2138-2146.
49. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001; 159: 651-659.
50. Boocock CA, Charnock-Jones DS, Sharkey AM, Mclaren J, Barker PJ, Wright KA et al. Expression of vascular endothelial growth factor and its receptors flt and kdr in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
51. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant overexpression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27-34.
52. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12: 129-135.
53. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000; 115: 1000-1007.
54. Little M, Kipriyanov SM, Gall FL, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today 2000; 21: 364-370.
55. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000; 21: 371-378.